ASX-listed company show successful results from first clinical trial - portable medical imaging technology

But you never say how fast you are. Can you even compete with these other fast diagnosis tools? It still seems to require a neurologist which I think needs to be removed from the equation. But since I'm not medically trained I will just shut up and be quiet, your stroke medical professionals will explain how fast you need to be treated to get 100% recovery and EXACTLY how this technology will do that. 

Hats off to Helmet of Hope - stroke diagnosis in 30 seconds   February 2017

 

Microwave Imaging for Brain Stroke Detection and Monitoring using High Performance Computing in 94 seconds March 2017

 

New Device Quickly Assesses Brain Bleeding in Head Injuries - 5-10 minutes April 2017

The latest here:

ASX-listed company show successful results from first clinical trial

by Sophia Katsinas

29 April 2020

EMVision Medical Devices Ltd (EMV), a company that took part in Switzer’s Small and Micro Cap Investor Day on 3 March 2020, has released new information on the ASX, releasing the preliminary images from their clinical trial.
READ MORE: https://switzer.com.au/the-experts/sophia-katsinas/a-taste-of-switzers-small-and-micro-cap-investor-day-event/
EMVision aims to revolutionise the imaging of strokes and traumatic brain injuries through the development and commercialisation of portable medical imaging technology.
Its first brain scanner is a commercial product at a manageable price that allows for quick, efficient and scalable brain scanning. EMVision’s scanners display strong correlation with CT and MRI scanners. The clinical assessment results show these similarities that produce the detection and localisation of abnormal brain tissue. The advantage of the EMV images, as shown in the images below, is that the EMV images distinguish abnormal brain tissue from healthy brain tissue, which apparently is often less clear in CT scans.

The technology is currently in the clinical trial stage, and the company has its hat in the ring for a share in a $50 million+ Medical Research Future Fund Grant pledged with the Australian Stroke Alliance.
Co-chairs of the Australian Stroke Alliance and past presidents of the World Stroke Organization, Professors Stephen Davis AM and Geoffrey Donnan AO said the results of the trial were “promising”. Professor Davis commented “These early images are clinically promising, clearly showing the effects of ischemic stroke in the same region as the gold standard imaging methods”. While Professor Donnan said “the lightweight portability of the device makes it a potential candidate for emergency stroke imaging in the prehospital setting.”
The machine will be accessible in the prehospital triage stage, meaning parademics and on-the-scene medical professionals will be able to identify the issue earlier, allowing for more targeted treatment options.
EMVision CEO, Dr Ron Weinberger was pleased with the result, saying “We are confident that as we continue to process further stroke patient data, we will demonstrate our unique value proposition to meet a major unmet clinical need in rapid and portable stroke diagnosis and monitoring.”